Reducing Lung Disease in Cystic Fibrosis: Model Systems and Anti-inflammatory Treatment PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Reducing Lung Disease in Cystic Fibrosis: Model Systems and Anti-inflammatory Treatment PDF full book. Access full book title Reducing Lung Disease in Cystic Fibrosis: Model Systems and Anti-inflammatory Treatment by Scotty McGlothlin Buff. Download full books in PDF and EPUB format.
Author: Scotty McGlothlin Buff
Publisher:
ISBN: 9780549012481
Category :
Languages : en
Pages : 241
Get Book Here
Book Description
These studies support that inflammation is excessive to bacterial infection in CF and demonstrate AAV-based IL-10 gene transfer is a promising anti-inflammatory therapeutic for CF lung disease.
Author: Scotty McGlothlin Buff
Publisher:
ISBN: 9780549012481
Category :
Languages : en
Pages : 241
Get Book Here
Book Description
These studies support that inflammation is excessive to bacterial infection in CF and demonstrate AAV-based IL-10 gene transfer is a promising anti-inflammatory therapeutic for CF lung disease.
Author: Carla Maria Pedrosa Ribeiro
Publisher: Frontiers Media SA
ISBN: 2889719413
Category : Science
Languages : en
Pages : 286
Get Book Here
Book Description
Author: Arata Azuma
Publisher: Springer
ISBN: 3034809778
Category : Medical
Languages : en
Pages : 266
Get Book Here
Book Description
This volume describes the pathogenesis and pathophysiology of several pulmonary diseases as well as their treatment. It also discusses the underlying genetic and molecular biological basis, which opens the way for new treatments for these conditions. It focuses on the treatment of cystic fibrosis including CFTR (cystic fibrosis transmembrane-conductance regulator) modulator therapies, drug therapies that augment airway surface liquid as well as anti-inflammatory and anti-infective therapies. Further topics include long-term, low-dose macrolide therapy for diffuse panbronchiolitis; novel agents for previously untreatable idiopathic pulmonary fibrosis; possible new treatments for pulmonary alveolar proteinosis (PAP); and multiple novel therapeutic targets for treating lymphangiomyomatosis. Research into these conditions has led to major advances in our understanding of the underlying genetic and molecular basis of this disease, and to dramatic improvements in survival and quality of life for affected individuals.
Author: Bruce K. Rubin
Publisher: Springer Science & Business Media
ISBN: 9783764359256
Category : Medical
Languages : en
Pages : 300
Get Book Here
Book Description
Although the potential for immunomodulation has been recognized for many years there has been an explosion of data in this field with relevance especially to the treatment of chronic airway diseases. Most of the work in this field has been conducted by Japanese investigators but in the last decade there has been a body of work outside of Japan that supports and enhances these findings. The book covers basic research like effects on bacteria, anti-inflammatory and mucoregulatory effects, but also clinical results with up-to-date information for the use of such medications to potentially treat diseases as diverse as chronic airway diseases, arthritis, inflammatory bowel disease, and cancer. The volume is intended for pulmonary physicians, researchers in inflammation research, and pharmaceutical companies interested in the development of such agents. It provides background information for the clinician as well as in depth exploration of cutting edge science.
Author: Kwakye Peprah
Publisher:
ISBN:
Category :
Languages : en
Pages : 25
Get Book Here
Book Description
Cystic fibrosis (CF) is a rare chronic genetic disease that affects multiple systems in the body including the respiratory tract, pancreas, gastro-intestinal tract and liver. The disorder is caused by mutations of the CF transmembrane conductance regulator (CFTR) gene. Approximately, one in 25 Canadians carries an abnormal CFTR gene, and CF occurs in children who inherit two abnormal genes, one from each parent. It is estimated that one in every 3,600 children born in Canada has CF, with more than 4,300 Canadian children, adolescents, and adults with CF attending specialized CF clinics. The disease has no cure at present, and it is the most common fatal genetic disease affecting Canadian children and young adults. Lung disease is the most prominent manifestation of CF, and it is reported to account for nearly 85% of deaths. Respiratory tract abnormalities in CF patients cause mucus plugging of the airways, bronchial wall thickening due to inflammation, increased susceptibility to respiratory tract infection, and airway destruction. Much of the pulmonary damage begins with lung inflammation. Although a normal inflammatory response is beneficial to host defence mechanisms, and helps to prevent the spread of infection, the excessive inflammation seen in CF patients is harmful as it contributes to the disease and associated death. One of the goals in the treatment of cystic fibrosis is to reduce lung inflammation. Corticosteroids are potent anti-inflammatory drugs which have been widely used in the treatment of a variety of diseases with underlying inflammation including asthma and chronic obstructive pulmonary disease (COPD). They exert direct inhibitory effects on many inflammatory cells, and regular use of inhaled corticosteroids (ICS) has been reported to reduce the number of mast cells within the airways, decrease airway microvascular leakage, and lessen mucus production. Although benefit of its use in CF has not been proven, ICS has been widely prescribed as anti-inflammatory agents to treat children and adults with CF empirically. The objective of this report is to summarize the evidence regarding the clinical effectiveness of ICS for the treatment of CF.
Author: Kamal Dua
Publisher: Academic Press
ISBN: 0128208880
Category : Technology & Engineering
Languages : en
Pages : 620
Get Book Here
Book Description
Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems explores the development of novel therapeutics and diagnostics to improve pulmonary disease management, looking down to the nanoscale level for an efficient system of targeting and managing respiratory disease. The book examines numerous nanoparticle-based drug systems such as nanocrystals, dendrimers, polymeric micelles, protein-based, carbon nanotube, and liposomes that can offer advantages over traditional drug delivery systems. Starting with a brief introduction on different types of nanoparticles in respiratory disease conditions, the book then focuses on current trends in disease pathology that use different in vitro and in vivo models. The comprehensive resource is designed for those new to the field and to specialized scientists and researchers involved in pulmonary research and drug development. Explores recent perspectives and challenges regarding the management and diagnosis of chronic respiratory diseases Provides insights into how advanced drug delivery systems can be effectively formulated and delivered for the management of various pulmonary diseases Includes the most recent information on diagnostic methods and treatment strategies using controlled drug delivery systems (including nanotechnology)
Author: Janette K. Burgess
Publisher: Springer Nature
ISBN: 303029403X
Category : Science
Languages : en
Pages : 260
Get Book Here
Book Description
This book presents state-of-the-art pre-clinical models and clinical applications of stem-cell-based therapies applied to different lung diseases, with a special focus on the translation of bench data into clinical studies. Starting with the assumption that abnormal lung tissue repair and regeneration has emerged as the driving force underlying pathogenesis and progression in many lung diseases, it sheds new light on the potential of stem/stromal cells as drivers of repair and sources of reparative factors in the lung. The first part of the book offers an overview of stem cell types and mechanisms involved in lung development, homeostasis, repair and regeneration, and reveals the crucial role of the extracellular matrix within the lung microenvironment. In the second part, leading experts present the latest pre-clinical evidence and clinical applications of stem-cell-based therapies in a wide variety of lung diseases, ranging from COPD and lung fibrosis to other rare lung diseases. The last section discusses stem cell delivery systems and devices, such as aerosolised spray application. This book appeals to pneumologists, stem cell and matrix biologists, as well as bioengeneers with a special interest in regenerative medicine applied to pulmonary diseases.
Author: Venkataramana K Sidhaye
Publisher: Academic Press
ISBN: 0128038810
Category : Medical
Languages : en
Pages : 277
Get Book Here
Book Description
Lung Epithelial Biology in the Pathogenesis of Pulmonary Disease provides a one-stop resource capturing developments in lung epithelial biology related to basic physiology, pathophysiology, and links to human disease. The book provides access to knowledge of molecular and cellular aspects of lung homeostasis and repair, including the molecular basis of lung epithelial intercellular communication and lung epithelial channels and transporters. Also included is coverage of lung epithelial biology as it relates to fluid balance, basic ion/fluid molecular processes, and human disease. Useful to physician and clinical scientists, the contents of this book compile the important and most current findings about the role of epithelial cells in lung disease. Medical and graduate students, postdoctoral and clinical fellows, as well as clinicians interested in the mechanistic basis for lung disease will benefit from the books examination of principles of lung epithelium functions in physiological condition. Provides a single source of information on lung epithelial junctions and transporters Discusses of the role of the epithelium in lung homeostasis and disease Includes capsule summaries of main conclusions as well as highlights of future directions in the field Covers the mechanistic basis for lung disease for a range of audiences
Author: Prashant Mohite
Publisher: BoD – Books on Demand
ISBN: 1838810730
Category : Medical
Languages : en
Pages : 126
Get Book Here
Book Description
Cystic fibrosis, a genetic disorder in children and young adults, is a multisystemic disease that mainly affects the lungs. Advances and improvements in the diagnosis and management of this condition have led to increased overall and symptom-free survival in cystic fibrosis patients. This book examines recent advances in the field and presents an evidence-based approach to the management of cystic fibrosis.
Author: United States. Public Health Service. Office of the Surgeon General
Publisher:
ISBN:
Category : Government publications
Languages : en
Pages : 728
Get Book Here
Book Description
This report considers the biological and behavioral mechanisms that may underlie the pathogenicity of tobacco smoke. Many Surgeon General's reports have considered research findings on mechanisms in assessing the biological plausibility of associations observed in epidemiologic studies. Mechanisms of disease are important because they may provide plausibility, which is one of the guideline criteria for assessing evidence on causation. This report specifically reviews the evidence on the potential mechanisms by which smoking causes diseases and considers whether a mechanism is likely to be operative in the production of human disease by tobacco smoke. This evidence is relevant to understanding how smoking causes disease, to identifying those who may be particularly susceptible, and to assessing the potential risks of tobacco products.
